for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allena Pharmaceuticals Inc

ALNA.OQ

Latest Trade

2.17USD

Change

0.00(0.00%)

Volume

25,281

Today's Range

--

 - 

--

52 Week Range

0.53

 - 

3.39

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.17
Open
0.00
Volume
25,281
3M AVG Volume
21.93
Today's High
--
Today's Low
--
52 Week High
3.39
52 Week Low
0.53
Shares Out (MIL)
48.52
Market Cap (MIL)
81.51
Forward P/E
-1.75
Dividend (Yield %)
--

Latest Developments

More

Orin Hirschman Reports 8.0% Passive Stake In Allena Pharmaceuticals Inc As Of January 20, 2021 - SEC Filing

Allena Pharmaceuticals Announces $10 Million Bought Deal Offering

Allena Pharma Announces Initial Data From Phase 1 Trial Of ALLN-346

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Allena Pharmaceuticals Inc

Allena Pharmaceuticals, Inc. is a late-stage, clinical biopharmaceutical company. The Company is focused on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. It is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Its pipeline includes reloxaliase and ALLN-346. Reloxaliase is an oral enzyme therapeutic that is being developed for the treatment of hyperoxaluria. ALLN-346 is designed to be an orally-administered non-absorbed urate-degrading enzyme. ALLN-346 is being developed to degrade urate in the gastrointestinal (GI) tract.

Industry

Biotechnology & Drugs

Contact Info

1 Newton Executive Park Ste 202

NEWTON, MA

02462-1435

United States

+1.617.4674577

http://www.allenapharma.com/

Executive Leadership

Alexey L. Margolin

Chairman of the Board, Co-Founder

Louis Brenner

President, Chief Executive Officer, Director

Edward Wholihan

Chief Financial Officer

Geoffrey Swire

Acting Chief Operating Officer, Interim Principal Operating Officer, Senior Vice President - Corporate Development

Ann Calby Miller

Director

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-4.800

2018

-1.720

2019

-2.130

2020(E)

-0.958
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.52
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
54.30
LT Debt To Equity (MRQ)
54.30
Return on Investment (TTM)
-112.54
Return on Equity (TTM)
-90.84

Latest News

Latest News

BRIEF-Empery Asset Management Lp Reports 8.71% Passive Stake In Allena Pharmaceuticals As Of June 3

* EMPERY ASSET MANAGEMENT LP REPORTS 8.71% PASSIVE STAKE IN ALLENA PHARMACEUTICALS AS OF JUNE 3 - SEC FILING Source text - https://bit.ly/2ARAr0b Further company coverage:

BRIEF-Allena Pharmaceuticals Announces $15.0 Mln Registered Direct Offering

* ALLENA PHARMACEUTICALS ANNOUNCES $15.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

BRIEF-Allena Pharmaceuticals Reports Q1 Loss Per Share Of $0.31

* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Allena Pharmaceuticals Reports Q4 Loss Per Share Of $0.47

* ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER 2019 AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Allena Pharma Announces Streamlined Design For Urirox-2, Second Pivotal Clinical Trial Of Reloxaliase For Enteric Hyperoxaluria

* ALLENA PHARMACEUTICALS ANNOUNCES STREAMLINED DESIGN FOR URIROX-2, SECOND PIVOTAL CLINICAL TRIAL OF RELOXALIASE FOR ENTERIC HYPEROXALURIA

BRIEF-Allena Pharmaceuticals Reports Q1 Loss Per Share $0.38

* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Allena Pharmaceuticals Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $0.48

* ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Allena Pharmaceuticals Initiates First Phase 3 Trial For ALLN-177 In Patients With Enteric Hyperoxaluria

* ALLENA PHARMACEUTICALS INITIATES FIRST PHASE 3 TRIAL FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up